Alkermes (NasdaqGS:ALKS) has started Phase 3 Brilliance Studies for alixorexton, an orexin 2 receptor agonist for narcolepsy ...

Alkermes PLC (NASDAQ:ALKS) is one of the 10 Stocks Dominating Today’s Market Surge. Alkermes extended gains for a second day ...

Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy ...

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in ...

An expert pharmacovigilance and clinical safety leader with more than 20 years of experience in his field, Vasudev Bhupathi ...

Ten stocks soared by double digits on Tuesday, outperforming Wall Street, as investors took heart from a flurry of corporate ...

Alkermes (NASDAQ:ALKS) shares rose 13% Tuesday following Eli Lilly’s (NYSE:LLY) announcement to acquire Centessa ...

Shares of Alkermes (NASDAQ:ALKS) climbed about 13% on Tuesday after Eli Lilly (NYSE:LLY) revealed plans to acquire Centessa ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Alkermes, with a price target of $43.00. Amsellem covers the Healthcare sector, focusing on stocks such as ...

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Alkermes, with a price target of $40.00.

— Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes’ Current Executive Vice ...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, ...